Navigation Links
Ardelyx to Present at the Wedbush 2014 Life Sciences Management Access Conference
Date:8/5/2014

FREMONT, Calif., Aug. 5, 2014 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that Mike Raab, Ardelyx's President and Chief Executive Officer, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 2:30pm Eastern Time at the Le Parker Meridien Hotel in New York City. 

Individuals who are interested in listening to the live presentation can participate via webcast at http://wsw.com/webcast/wedbush28/ardx. A copy of the presentation will also be available at http://www.ardelyx.com.

About Ardelyx, Inc.

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, a product currently in three separate Phase 2 clinical trials for the treatment of constipation-predominant irritable bowel syndrome (IBS-C), complications associated with end-stage renal disease (ESRD), and chronic kidney disease (CKD).

Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In addition to tenapanor, the Company is evaluating small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD, a program licensed to Sanofi, and is independently is advancing several additional research programs focused in cardio-renal, GI and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx's website at www.ardelyx.com.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995.  Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.  Ardelyx undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's prospectus filed with the Securities and Exchange Commission on June 19, 2014, and its future periodic reports to be filed with Securities and Exchange Commission.  


'/>"/>
SOURCE Ardelyx, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Intrexon to Present at Jefferies 2014 Global Industrials Conference
2. Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference
3. TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner
4. Dmitry Medvedev Presented BIOCAD the First National "Industry" Award
5. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
6. Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
7. MiMedx to Present at 32nd Annual J.P. Morgan Healthcare Conference
8. Spherix Secures License For CompuFill Patents - Agreement Represents Spherix Second License Agreement Under New License Campaign
9. New Technology and Healthcare Environment Present Both Challenges and Opportunities for Pharmaceutical Call Centers
10. Halozyme Therapeutics To Present At The 32nd Annual J.P. Morgan Healthcare Conference
11. Generex Announces Selection of Antigen Express Technology for Keynote Presentation at 2014 TIDES Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , ... March 21, 2017 , ... The Conference Forum ... (CMO Summit) to be held on May 10-11, 2017, at the Colonnade Hotel in ... specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical ...
(Date:3/22/2017)... ... March 22, 2017 , ... March 22, 2017...Council for ... another green revolution, one that utilizes technological innovation in smart, sustainable ways. Humans depend ... life such as aesthetics and environmental stability. This paper is the first in a ...
(Date:3/22/2017)... SAN FRANCISCO , March 22, 2017 /PRNewswire/ ... the fastest growing genetic information companies, today announced ... the diagnosis of Spinal Muscular Atrophy (SMA) ... the leading lethal genetic disorders among infants as ... disease in childhood. The new test, announced during ...
(Date:3/20/2017)... Diego, CA (PRWEB) , ... March 20, 2017 ... ... novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into ... (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) ...
Breaking Biology Technology:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
Breaking Biology News(10 mins):